Industry news · event 2026-01-20 · 3 min read
Oral Wegovy Launches: FDA-Approved Semaglutide in a Pill, $149 Introductory (Early 2026)
The Wegovy tablet arrived in early 2026 with roughly injectable-class efficacy, strict empty-stomach rules, and a $149/month introductory price that briefly undercut most of the compounded market.
GRGLP1ProviderCompare Research Team
Pricing & policy research
Quick answerThe Wegovy tablet arrived in early 2026 with roughly injectable-class efficacy, strict empty-stomach rules, and a $149/month introductory price that briefly undercut most of the compounded market.
Needle-free stopped being a compromise in early 2026: high-dose oral semaglutide — the Wegovy tablet — launched with trial results in the neighborhood of injectable semaglutide (~15% average loss in the OASIS program) and an introductory price of $149 a month on its lower doses.
Two conditions define the product. First, the ritual: SNAC-assisted absorption only works on a truly empty stomach — first thing, ≤4 oz of plain water, a 30-minute wait before anything else — making daily discipline the price of skipping the weekly needle. Second, the price path: $149 is introductory and dose-limited, reverting toward NovoCare's standard $349 structure, with government-program beneficiaries excluded from cash offers.
The competitive effect was immediate and strange: for the intro window, an FDA-approved product undercut all but a handful of verified compounded semaglutide programs in our rankings — a sentence that would have been unprintable in 2024. Full rules, fit, and math: the Wegovy pill, explained.